



NANOLOGICA

INTERIM REPORT JAN-MAR 2022
NANOLOGICA AB (PUBL)

PERIOD IN BRIEF

FINANCIAL SUMMARY

- Net sales for the first quarter amounted to TSEK 270 (5,622)
- The operating result amounted to TSEK -15,592 (-6,768)
- Result after tax amounted to TSEK -15,915 (-7,845)
- Earnings per share before and after dilution were SEK -0.57 (-0.28)
- Cash and cash equivalents amounted to TSEK 3,969 (57,069) as per March 31, 2022

SIGNIFICANT EVENTS IN THE FIRST QUARTER

- In January, a credit facility of up to MSEK 50 was signed with the company's principal owner Flerie Invest AB. In connection with the signing of the credit facility, a loan of MSEK 10 within the same was taken. The credit facility agreement is approved by a subsequent extraordinary general meeting on February 7, 2022.
- Nanologica's shares were admitted to trading on Nasdaq Stockholm Main Market on March 29, 2022.
- Katarina Alenäs took office as SVP Chromatography to lead the company's sales organization in chromatography globally.

SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

- Launch of the company's silica for preparative chromatography, NLAB Saga®, has started
- In April, a loan of MSEK 20 was taken within the credit facility that was signed with Flerie Invest AB in January.

Key Figures (group)	2022	2021	2021
	Jan - Mar	Jan - Mar	Jan-Dec
Net sales (TSEK)	270	5 622	12 914
Operating profit/loss (TSEK) *	-15 592	-6 768	-40 689
Profit/Loss before income tax (TSEK)	-15 915	-7 845	-44 829
Cash flow from operating activities (TSEK)	-14 744	-3 476	-46 493
Cash and cash equivalents (TSEK)	3 969	57 069	10 987
Total equity (TSEK)	35 681	85 103	51 596
Average number of shares	28 165 826	27 788 212	27 995 090
Number of shares, end of period	28 165 826	27 794 480	28 165 826
Earnings per share (basic and diluted) (SEK)	-0,57	-0,28	-1,60
Equity per share (SEK) *	1,27	3,06	1,83
Equity ratio (%) *	39%	61%	52%
Average number of employees	17	18	19
Number of employees, end of period	18	20	17

* Alternative key figures that are not defined by IFRS. For definition, please see note 9.

Amounts in brackets refer to comparative figures for the corresponding period of the previous year. The quarter refers to January – March 2022. Unless otherwise stated, this interim report refers to the group.

This report in English is a translation of the original report in Swedish. In case of any discrepancies, the report in Swedish has precedence.

CEO COMMENT

A NEW CHAPTER BEGINS

On March 29, 2022, a new chapter in Nanologica's history began – as listed on a regulated market. By listing the share on Nasdaq Stockholm Main Market, we get an increased exposure and a better opportunity to attract institutional and international owners.

At the same time, we are now launching our products for preparative chromatography.



The big event of the quarter was the change of lists to Nasdaq Stockholm Main Market, which we conducted on March 29. Being approved for trading on the main market puts a seal of quality on the company and the development we are pursuing. We have processes and procedures in place to run the company in line with the requirements of a regulated market, which means that the share is made more accessible to both Swedish and foreign institutional investors.

The company's main focus is currently on launching NLAB Saga®, our silica for preparative chromatography. Our newly appointed SVP Chromatography Katarina Alenäs and I started the launch with a successful conference in India in April and now a string of activities during the second and third quarters will follow. It is very gratifying to finally be able to travel again to meet customers. To now do so when we launch a world-class product, which can enable reduced production costs for insulin and other peptide drugs, feels fantastic. We see a high level of activity in the development of peptide drugs and experienced a great interest in our products. In light of this, we maintain our beliefs that it is reasonable to reach sales in Chromatography of MSEK 100–300 by 2024.

Production of our first commercial silica for preparative chromatography is almost finalized and with the eased travel restrictions, we have been able to increase our presence at the contract manufacturer in England. If nothing unforeseen happens, our assessment remains that products for sale will be available in the second quarter of 2022.

2022 has started strongly, although the progress we have made is not yet visible in our books. When we have launched our products for preparative chromatography, the possibility for ramping up the company's turnover increases significantly. We are more than ready to write new chapters in the history of Nanologica.

Södertälje in April

/Andreas Bhagwani, CEO

NANOLOGICA IN BRIEF

Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products.

Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world.

In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. The goal is to establish a fast-growing, sustainable, and profitable business by providing silica-based products for the analysis and purification of substances, with a focus on diabetes products.

In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung. Drug substances are loaded inside the pores of silica particles and in this way, the solubility and bioavailability of a drug substance can be improved, substances can be protected from degradation, and more types of substances, among which biologics, can be formulated for inhalation. The platform is developed in order to provide new treatment options for patients with lung diseases. The goal is to create long-term values both with own products, as well as together with partners.

Nanologica has a small research and production facility at the headquarter in Södertälje, where development of new products and production of silica in small scale is conducted. Since 2019, the company has invested in large-scale production capacity at a contract manufacturer in Great Britain. The large-scale facility has successfully produced material that is identical to the material produced at the pilot plant in Södertälje and has the capability of producing silica under cGMP.

Nanologica's share (NICA) is listed on Nasdaq Stockholm Main Market since March 29, 2022. For further information, please visit

www.nanologica.com.



NANOLOGICA

BUSINESS AREA CHROMATOGRAPHY

Commercial silica for preparative chromatography at ton scale is being completed in the final stages of production, and delivery of the first products is approaching. The company maintains its assessment that products for sale will be available during the second quarter of 2022.

Following eased travel restrictions, Nanologica has increased its presence at the contract manufacturer Sterling Pharma Solutions in England, to actively work with processes in the factory. The production time for this first campaign has been very long as each step has been tuned during the process, at the same time as the pandemic has caused delays in deliveries of, for example, spare parts. The contract manufacturer Sterling Pharma Solution is a long-term partner of Nanologica and once this first production campaign has been completed, the focus will be on streamlining processes and shortening lead times for subsequent campaigns.

The launch of Nanologica's products for preparative chromatography has begun. As part of the launch, the company participates in several conferences for preparative chromatography during the year in both India and the USA as well as in Europe. During the first quarter, Katarina Alenäs has taken office as SVP Chromatography to lead the sales organization globally. Nanologica thus has an own sales organization that covers all major markets. The sales team is supported by an application and

product development team that supports customers in method development and problem solving, in order to create a stronger customer offering.

Net sales for the Chromatography business area amounted to TSEK 270 (141) for the first quarter. Sales of analytical columns amounted to TSEK 234, where China, followed by Egypt, accounted for the largest part of the turnover. Sample materials for preparative chromatography were sold to customers during the quarter at a value of TSEK 36. The increase in net sales for the quarter is attributed to a slightly increased sales of analytical columns, compared to the previous year, which was severely affected by the effects of the Corona pandemic. As the company's focus in Chromatography is primarily on preparative chromatography, sales of analytical columns are expected to remain at limited levels in the coming quarters.

Operating result for the quarter amounted to TSEK -4,796 (-3,324). The operating result was affected by lower sales as well as by the disposal of obsolete inventory of TSEK 1,082 in accordance with the company's strategy of increased focus on preparative chromatography. Furthermore, full depreciation of assets linked to large-scale production has been made since the second quarter of 2021. Depreciation and amortization in the group linked to large-scale production amounted to TSEK 1,596 during the first quarter.

Chromatography	2022	2021	2021
	Jan - Mar	Jan - Mar	Jan - Dec
Net sales, TSEK	270	141	1 911
Raw materials, consumables and change in inventory. TSEK	-1 350	131	-4 389
Gross profit, TSEK	-1 080	272	-2 478
Operating result, TSEK	-4 796	-3 324	-19 417
Average number of employees	7	9	8

BUSINESS AREA DRUG DEVELOPMENT

During 2021, the strategy in Drug development was refocused to inhaled drugs and respiratory diseases. Following this, the company has taken a step back to build a solid foundation with robust data before the company's inhalation platform for the delivery of drugs locally to the lung is taken further towards clinical studies. This means that candidates for clinical development are not expected to be presented until next year. However, Nanologica believes that the opportunities to conduct economically more favorable projects with a higher chance of success increase with a solid foundation in place.

During the first quarter, progress has been made regarding the technical development of the inhalation platform. The focus is on particle design and specifically on modification of particle properties to adapt them to various treatment intervals, such as one, two or three times a day. This is done in order to control clearance, that is how quickly the particles are dissolved and eliminated from the lung.

Since no adequate methods for measuring

clearance of NPP (nanoporous particles) in the lung have been available, the company has developed an in vivo methodology for this, which has been evaluated in a pilot study. The results of the pilot study have since formed the basis for the work to ensure appropriate particle design to be able to control clearance, with the purpose of making the technology useful in a variety of dosing regimens. Clearance studies will continue throughout the year to measure these elimination rates in different variants of particles, both empty particles and particles loaded with drug substances. These studies will then form the basis for safety studies with the drug candidates that are later selected for clinical development.

Net sales for the Drug Development business area amounted to TSEK 0 (5,481) for the quarter. The decrease for the quarter is attributed to the final delivery of the partner project with Vicore Pharma being in the fourth quarter of 2021. Operating profit for the quarter amounted to TSEK -3,031 (-111).

Drug Development	2022	2021	2021
	Jan - Mar	Jan - Mar	Jan - Dec
Net sales, TSEK	0	5 481	10 361
Raw materials, consumables and change in inventory. TSEK	-7	-2 475	-4 770
Gross profit, TSEK	-7	3 006	5 591
Operating result, TSEK	-3 031	-111	-6 075
Average number of employees	5	6	7

OPERATING INCOME AND RESULT

Net revenue for the quarter amounted to TSEK 270 (5,622). Net revenue is mainly related to revenues from sales of analytical columns within the Chromatography business area. Included in the comparison numbers are revenue from the partner project with Vicore Pharma within Drug Development which was delivered in full during the fourth quarter 2021.

The operating result for the quarter amounted to TSEK -15,592 (-6,768). The operating result was mainly affected by lower net sales and by change in inventory amounting to TSEK -1,223 (723), mainly related to disposal of obsolete goods. The operating result for the quarter was also affected by increased personnel costs amounting to TSEK 6,795 (5,086), by TSEK 2,887 (1,763) relating to depreciations where the increase is related to the scaling up of silica production, and by TSEK 1,960 related to re-listing at Nasdaq Stockholm.

Net financial items for the quarter amounted to TSEK -323 (-1,079). Net financial items were positively impacted by the valuation of market-listed shares at fair value.

The result after tax for the quarter amounted to TSEK -15,915 (-7,845).

Earnings per share before and after dilution for the quarter were SEK -0.57 (-0.28).

TAX

The company pays taxes and fees in accordance with applicable legislation. As regards to tax on profit or loss, the company does currently not pay any tax due to negative earnings. As of December 31, 2021, the group had tax loss deductions amounting to TSEK 203,563 and the parent company had tax loss deduction amounting to TSEK 207,324. The tax loss deductions may be activated when the requirements for activation of the deferred tax asset are met. The tax loss deductions are not time limited.

INVESTMENTS, LIQUIDITY AND FINANCIAL POSITION

On March 31, 2022, capitalized expenses for development work amounted to TSEK 11,768, compared to TSEK 12,299 at the beginning of the

year. These expenses mainly relate to costs for products within Chromatography and Drug Development, and development costs for upscaling to large-scale production of silica. The patent portfolio amounted to TSEK 1,896 compared to TSEK 1,880 at the beginning of the year.

The book value of right-of-use assets amounted to TSEK 23,450 compared to TSEK 25,085 at the beginning of the year, mainly relating to dedicated equipment for large-scale production of silica at the contract manufacturer Sterling Pharma Solutions. The book value of tangible fixed assets amounted to TSEK 2,289 compared to TSEK 2,248 at the beginning of the year. Prepaid production costs amounted to TSEK 41,585 (22,357) on the balance sheet date, which relates to advances to Sterling Pharma Solutions for ongoing production of the first ton scale campaign of Nanologica's silica.

Total cash flow for the quarter amounted to TSEK -7,040 (-9,304).

Cash flow for operating activities for the quarter amounted to TSEK -14,744 (-3,476). Cash flow from operating activities has been negatively affected by the company being in an expansion phase with increased costs and payments for ongoing large-scale production.

Cash flow from investment activities amounted to TSEK -942 (-4,598). The investments during the quarter are mainly related to intangible assets in the form activated work for own account connected to the company's inhalation platform, as well as patents and patent applications.

Cash flow from financial activities amounted to TSEK 8,646 (-1,230). During the quarter, a loan of MSEK 10 was taken within the credit facility of up to MSEK 50 that was agreed with Flerie Invest AB in January 2022.

As per March 31, 2022, cash and cash equivalents amounted to TSEK 3,969 (57,069). After the period, a further loan of MSEK 20 has been taken within the above-mentioned credit facility with the purpose of covering the company's temporary financial needs pending expected cash flows from the preparative chromatography business. Thus, MSEK 20 of the credit line is unused.

Total equity amounted to TSEK 35,681 compared to TSEK 51,596 at the beginning of the year. The equity/assets ratio was 39 percent compared to 52 percent at the beginning of the year.

FLUCTUATIONS IN REVENUE GENERATION

Nanologica has two business areas that generate revenue.

Chromatography generates revenue through the sales of products for analytical and preparative chromatography. Sales of products for preparative chromatography are expected to start during the first half of 2022. The sales of products for analytical chromatography will then be of a supportive nature and not the main business.

Drug Development has so far generated revenues from partner collaborations and licensing agreements. Revenues fluctuate depending on the nature, phase, and structure of the projects, which means that larger projects and agreements can have significant effects on revenue and result for individual quarters. Revenue and result developments should therefore be assessed over a longer period of time.

Nanologica lacks significant seasonal variations.

EMPLOYEES AND ORGANIZATION

As per March 31, 2022, the number of permanent employees was 18 (19), whereof 8 in Chromatography, 5 in Drug Development and 5 in Business Support. 11 (13) were women and 6 (6) were men. 4 people work in R&D and out of the total number of employees, 6 are PhDs. To conduct an efficient business with a cost-effective organization, Nanologica hires consultants, advisors and project employees for specific assignments and tasks in areas of competence that the company lacks or only periodically needs. As per March 31, 2022, the number of consultants and project employees corresponds to 2,5 (3) full-time equivalents, of which 0,5 in Chromatography, 1 in Drug Development and 1 in Business Support.

PATENTS

At the end of the quarter, Nanologica's patent portfolio consisted of 6 patent families with more

than 30 granted patents and over 15 pending patent applications.

PARTNERSHIPS, COLLABORATIONS AND ESSENTIAL AGREEMENTS

No new partnerships, collaborations or essential agreements have been entered into during the first quarter. Further information is available in Nanologica's Annual Report 2021.

FUTURE PROSPECTS

This report contains forward-looking statements. Actual outcomes may differ from these statements. Internal and external factors can affect Nanologica's results.

When large-scale production of silica has been established, sales in preparative chromatography are expected to increase and make up the majority of Nanologica's revenue. The company considers it reasonable to achieve sales in preparative chromatography of MSEK 100-300 in 2024, based on the customer dialogues that are currently carried out.

Nanologica's projects in the Drug Development business area are expected to focus primarily on inhaled drugs and respiratory diseases. The company intends to run its own projects as well as projects with partners. Proving the technology in your own projects is expected to increase the possibility of economically advantaged partner projects. Positive cash flow from the Chromatography business area can facilitate the financing of the company's Drug Development business area, which requires significant investments before it is expected to generate greater revenue.

In 2022, the company's sales are expected to increase significantly, mainly due to sales of products for preparative chromatography. Costs are also expected to increase, both as a result of higher production costs in the Chromatography business area and costs for the inhalation program in the Drug Development business area.

RISKS AND UNCERTAINTIES

The company makes assumptions, assessments and estimates that affect the content of the financial statements. Actual outcomes may differ

from these assessments and estimates, as stated in the accounting principles. The goal of the group's risk management is to identify, prevent, measure, control and limit the risks in the business. Significant risks are the same for the parent company and the group.

The risks in Nanologica's operations include strategic risks related to, among other things, the company's operations, industry, legal and regulatory risks, such as financing of upscaling projects, commercialization, dependence on partners, research, trademarks, patents and external requirements, and operational risks such as production risks, price changes on raw materials and inputs. A detailed description of risk exposure and risk management can be found in Nanologica's Annual Report for 2021 on pages 56–60.

During the first quarter, the situation in Ukraine has arisen as a new uncertainty factor, as described below.

IMPACT OF COVID-19

As a result of the pandemic, delivery of a larger amount of product from large-scale production of silica has been delayed. In particular, it is the supply of equipment, raw materials and spare parts for new machines and rebuilding of machines and premises that has taken longer than expected and thus delayed the project. No further delays due to the pandemic are expected in the second quarter, but this cannot be ruled out.

Reinstated travel restrictions make it more difficult with travelling to and within China. The company therefore currently refrains from travelling to China.

THE WAR IN UKRAINE

During the first quarter, the war in Ukraine and the subsequent sanctions against Russia had no direct impact on the company or its employees. However, there is uncertainty in both the commodity market and the financial market. A protracted war may affect the supply of raw materials and components, as well as logistics. At the time of publication of the report, Nanologica does not conduct any business activities linked to either Ukraine or Russia.

THE SHARE AND OWNERS

Nanologica's share is listed on Nasdaq Stockholm Main Market since March 29, 2022. The ticker is NICA and the ISIN code is SE0005454873. There is one class of shares and all shares have equal voting rights as well as share of the company's assets and earnings. The company's share register is kept electronically by Euroclear Sweden AB. The number of outstanding shares at the end of the first quarter amounted to 28,165,826 and the market capitalization was approximately MSEK 472. The share capital amounted to SEK 11,548,771 SEK and the share quota was SEK 0.41.

Owners as of March 31, 2022	Shares	Share %
Flerie Invest AB	8,982,639	31.9
Swedbank Robur Microcap	2,546,501	9.0
Vega Bianca AB	2,014,764	7.2
Försäkringsaktiebolaget Avanza Pension	1,257,608	4.5
Konstakademien	1,250,000	4.4
Nordic Cross Asset Management	657,389	2.3
Niklas Sjöblom	561,953	2.0
Rahal Investment AB	467,389	1.7
Andre Oscar o Anna Wallenbergs stiftelse	345,000	1.2
CJ Hall Invest	332,000	1.2
The ten largest shareholders	18,415,243	65.4
Other shareholders (2,243)	9,750,583	34.6
Total	28,165,826	100.0

SHARE-BASED INCENTIVE PROGRAMS

There are three active stock option programs.

In the stock option program 2020/22 for the board of directors, all 350,000 options were subscribed and allocated. In the stock option program 2020/22 for the management and employees, 569,949 of the total 698,577 options were subscribed and allocated. Each option entitles the holder to subscribe for one share in the company at a subscription price corresponding to SEK 18, during the period 1 July 2020 to 1 July 2022. Based on the existing number of shares, the dilution will be a maximum of approximately 3.2 percent if all options are exercised.

During the fourth quarter, the option program 2021/2024, which was resolved by the Annual General Meeting on May 27, 2021, was implemented. In the program, all of the 800,000

options were subscribed for. Each option entitles the holder to subscribe for one share in the company at a subscription price corresponding to SEK 45, during the period 1 July 2021 to 1 July 2024. Based on the existing number of shares, the dilution will be a maximum of approximately 2.8 percent if all options are exercised.

During the first quarter, there were no changes within the option programs.

ACCOUNTING AND VALUATION PRINCIPLES

The group's accounting principles are based on IFRS. The group's interim report has been prepared in accordance with IAS 34 Interim Reporting and the Swedish Annual Accounts Act. The same accounting and valuation principles as in the most recent annual report have been applied. More information regarding accounting and valuation principles can be found on pages 72–80 in Nanologica's annual report 2021.

Amounts are expressed in TSEK and MSEK, which in this interim report refers to thousands of Swedish kronor and millions of Swedish kronor. Amounts in brackets refer to comparative figures for the previous year. Information for the quarter refers to the first quarter of 2021 unless otherwise stated.

RELATED PARTY TRANSACTIONS

First quarter

In January 2022 Nanologica signed an agreement with the company's principal owner Flerie Invest AB regarding a credit facility of up to MSEK 50. In connection to the signing of the agreement, a loan of 10 MSEK within the same was taken. The interest rate is 8 percent, and the loan is due for payment in July 2025. A commitment fee of 1 percent is included in the credit facility. The credit facility was approved by a subsequent extraordinary general meeting on February 7, 2022.

Payments to Flerie Invest AB during the quarter amounted to TSEK 1,119. The amount refers to interest for the current quarter for the period's additional loan, interest for the next quarter regarding both loans, and the commitment fee for the entire credit facility described above.

Costs during the quarter regarding loans from Flerie Invest AB amounted to TSEK 454 and relate to interest and commitment fee.

Loans from Flerie Invest AB were raised on market terms and amounted to MSEK 27 as of March 31, 2022. Loan 1 totaling MSEK 17 was raised during autumn 2019 and spring 2020. The interest rate is 8 percent, and the loan is due for payment in July 2023. Loan 2 totaling MSEK 10 was raised during the first quarter of 2022. The interest rate is 8 percent, and the loan is due for payment in July 2025. The total credit facility amounts to MSEK 50.

After the quarter

A loan of MSEK 20 was taken in April within the credit facility of up to MSEK 50 that was signed with Flerie Invest AB in January 2022.

Flerie Invest AB is owned by Thomas Eldered, who is a board member of Nanologica as well as the company's largest owner through Flerie Invest AB. More information on transactions with related parties can be found in Nanologica's annual report 2021, note 37.

FINANCIAL CALENDAR

Interim report Jan-Jun 2022	Aug 19, 2022
Interim report Jan-Sep 2022	Oct 28, 2022
Year-end report Jan-Dec 2022	Feb 10, 2023

Important events and financial reports are published through press releases and on the company's website www.nanologica.com, where they are also kept available. Through a subscription service on the company's website, it is possible to subscribe to Nanologica's reports and press releases via e-mail.

ANNUAL GENERAL MEETING

The annual general meeting will be held at The Park, Magnus Ladulås gata 1 in Stockholm on June 2, 2022, at 12.00.

AUDITORS REVIEW

is interim report has not been subject to review by the company's auditors.

ASSURANCE

The board of directors and the CEO provide their assurance that the interim report provides a fair and true overview of the parent company's and the group's operations, financial position, and results, and describes material risks and uncertainties faced by the parent company and the companies in the group.

April 28, 2022

Gisela Sitbon
Chairman of the board

Mattias Bengtsson
Board member

Eva Byröd
Board member

Thomas Eldered
Board member

Tomas Kramar
Board member

Anders Rabbe
Board member

Lena Torlegård
Board member

Andreas Bhagwani
Chief Executive Officer

For further information, please contact:
CEO Andreas Bhagwani, ph. +46-70-316 17 02
CFO Eva Osterman, ph. +46-72-180 30 75



FINANCIAL REPORTS AND NOTES

CONSOLIDATED INCOME STATEMENT

Amounts in TSEK	2022 Jan - Mar	2021 Jan - Mar	2021 Jan - Dec
Net sales	270	5 622	12 914
Change in inventory, finished goods	-1 223	723	-2 301
Capitalized work for own account	406	578	1 809
Other operating income	78	58	1 088
Operating expenses			
Raw materials and consumables	-134	-3 067	-7 502
Other external expenses	-5 017	-3 380	-12 583
Personnel costs	-6 795	-5 086	-21 222
Depreciation, amortization and impairment of plant, property, and equipment	-2 887	-1 763	-10 463
Other operating expenses	-290	-454	-2 430
Total operating expenses	-15 122	-13 750	-54 199
Operating profit/loss	-15 592	-6 768	-40 689
Financial items			
Valuation of financial assets at fair value	448	-256	-902
Financial income	22	8	3
Financial costs	-793	-828	-3 242
Total financial items	-323	-1 077	-4 140
Profit/loss before income tax	-15 915	-7 845	-44 829
Income tax	0	0	0
Profit/loss for the period attributable to owners of parent company	-15 915	-7 845	-44 829
Other comprehensive income	0	0	0
Total comprehensive profit/loss for the period attributable to owners of parent company	-15 915	-7 845	-44 829
Earnings per share (basic and diluted), SEK	-0,57	-0,28	-1,60
Average number of ordinary shares during the period	28 165 826	27 788 212	27 995 090
Ordinary shares outstanding at the closing date	28 165 826	27 794 480	28 165 826

CONSOLIDATED BALANCE SHEET

Amounts in TSEK	2022 Mar 31	2021 Mar 31	2021 Dec 31
ASSETS			
Noncurrent assets			
Intangible assets			
Capitalized expenses for development work and similar work	11 768	15 187	12 299
Concessions, patents, licenses, trademarks and similar rights	1 896	1 760	1 880
Total intangible assets	13 664	16 946	14 179
Tangible fixed assets			
Equipment, tools and installations	2 289	1 997	2 248
Right-of-use assets			
Right-of-use assets	23 450	27 920	25 085
Total noncurrent assets	39 403	46 864	41 512
Current assets			
Inventories			
Inventories	1 238	5 312	2 408
Current receivables			
Accounts receivable	317	2 966	1 421
Other receivables	768	146	493
Prepaid expenses and accrued income	43 531	24 828	40 780
Total current receivables	44 616	27 941	42 694
Financial assets (current)			
Financial assets at fair value through profit or loss	1 162	1 359	714
Cash and cash equivalents			
Cash and cash equivalents	3 969	57 069	10 987
Total current assets	50 985	91 681	56 803
TOTAL ASSETS	90 388	138 545	98 316

CONSOLIDATED BALANCE SHEET

Amounts in TSEK	2022 Mar 31	2021 Mar 31	2021 Dec 31
EQUITY AND LIABILITIES			
Equity			
Share capital including ongoing issues	11 549	11 397	11 549
Additional paid-in capital	234 674	231 349	234 674
Retained earnings incl. profit/loss from actual period	-210 542	-157 642	-194 627
Total equity	35 681	85 103	51 596
Total equity attributable to parent company shareholders	35 681	85 103	51 596
Noncurrent liabilities			
Liabilities to credit institutions	833	3 013	1 333
Lease liabilities	2 646	3 881	3 359
Provisions	533	528	530
Other noncurrent liabilities	36 502	27 000	27 000
Total noncurrent liabilities	40 515	34 422	32 222
Current liabilities			
Liabilities to credit institutions	2 180	2 720	2 360
Advanced payment from customers	779	2 590	946
Accounts payable	2 796	5 982	3 685
Lease liabilities	2 779	2 149	2 739
Other liabilities	1 233	884	1 443
Accrued expenses and deferred income	4 426	4 695	3 325
Total current liabilities	14 193	19 021	14 498
Total liabilities	54 707	53 442	46 719
TOTAL EQUITY AND LIABILITIES	90 388	138 545	98 316

CONSOLIDATED REPORT OF CHANGES IN EQUITY

Amounts in TSEK	2022 Jan - Mar	2021 Jan - Mar	2021 Jan - Dec
Total equity at the beginning of the period	51 596	92 966	92 966
Rights issue	0	0	3 453
Premiums for issued / repurchased warrants	0	-18	6
Total comprehensive income for the period	-15 915	-7 845	-44 829
Total equity at the end of the period	35 681	85 103	51 596

CONSOLIDATED CASH FLOW ANALYSIS

Amounts in TSEK	2022 Jan - Mar	2021 Jan - Mar	2021 Jan - Dec
Operating activities			
Operating profit/loss	-15 592	-6 768	-40 688
Adjustment for items not affecting cash flow	2 945	1 763	11 630
Interest paid	-1 288	-3 435	-5 565
Income taxes received/paid	0	0	0
Cash flow from operating activities before changes in working capital	-13 935	-8 440	-34 623
<i>Cash flow from changes in working capital</i>			
Increase (-) / decrease (+) of inventories	1 170	-723	2 182
Increase (-) / decrease (+) of operating receivables	-1 919	2 794	-12 237
Increase (+) / decrease (-) of operating liabilities	-60	2 894	-1 814
Cash flow from operating activities	-14 744	-3 476	-46 493
Investing activities			
Acquisitions in intangible assets	-655	-3 328	-5 122
Acquisitions in tangible fixed assets	-287	-29	-808
Acquisitions in right-of-use assets	0	-1 241	-1 319
Cash flow from investing activities	-942	-4 598	-7 249
Financing activities			
Rights issue for the year	0	0	3 454
Premiums for issued/reissued warrants	0	-19	-19
New borrowings	10 000	0	0
Amortization of lease liabilities	-674	-520	-2 343
Amortization of financial loans	-680	-690	-2 730
Cash flow from financing activities	8 646	-1 230	-1 639
Total cash flow for actual period	-7 040	-9 304	-55 381
Cash and cash equivalents, opening balance	10 987	66 364	66 364
Exchange rate difference in cash and cash equivalents	22	9	4
Cash and cash equivalents, closing balance	3 969	57 069	10 987

INCOME STATEMENT FOR PARENT COMPANY

Amounts in TSEK	2022 Jan - Mar	2021 Jan - Mar	2021 Jan - Dec
Net sales	270	5 622	12 914
Change in inventory, finished goods	-1 223	723	-2 301
Capitalized work for own account	406	578	1 809
Other operating income	78	58	1 088
Operating expenses			
Raw materials and consumables	-134	-3 067	-7 502
Other external expenses	-5 768	-3 941	-15 187
Personnel costs	-6 795	-5 086	-21 222
Depreciation, amortization and impairment of plant, property, and equipment	-2 296	-2 276	-9 245
Other operating expenses	-290	-454	-2 430
Total operating expenses	-15 282	-14 823	-55 586
Operating profit/loss	-15 752	-7 842	-42 075
Financial items			
Profit/loss from group companies	-27	-78	-282
Result/loss from other financial items	448	-256	-902
Currency effects	0	0	0
Interest income and similar income	22	8	3
Interest expense and similar expenses	-735	-764	-2 969
Profit/loss from financial items	-291	-1 091	-4 150
Profit/loss before income tax	-16 044	-8 933	-46 225
Income tax	0	0	0
Profit/loss for the period	-16 044	-8 933	-46 225

STATEMENT OF COMPREHENSIVE INCOME FOR PARENT COMPANY

Amounts in TSEK	2022 Jan - Mar	2021 Jan - Mar	2021 Jan - Dec
Profit/loss for the period	-16 044	-8 933	-46 225
Other comprehensive income			
Items that may be reclassified to result for the year	0	0	0
Comprehensive income for the period	-16 044	-8 933	-46 225

BALANCE SHEET FOR THE PARENT COMPANY

Amounts in TSEK	2022 Mar 31	2021 Mar 31	2021 Dec 31
ASSETS			
Noncurrent assets			
Intangible assets			
Capitalized expenses for development work and similar work	24 653	32 245	26 228
Concessions, patents, licenses, trademarks and similar rights	1 896	1 760	1 880
Total intangible assets	26 549	34 005	28 108
Tangible fixed assets			
Equipment, tools and installations	2 289	1 997	2 248
Financial non-current assets			
Participations in group companies	100	100	100
Total noncurrent assets	28 938	36 102	30 456
Current assets			
Inventories			
Inventories	1 238	5 312	2 408
Current receivables			
Accounts receivable	317	2 966	1 421
Receivables from group companies	0	61	24
Other receivables	759	139	464
Prepaid expenses and accrued income	44 794	26 219	42 087
Total current receivables	45 871	29 385	43 996
Financial assets (current)			
Financial assets at fair value through profit or loss	1 162	1 359	714
Cash and cash equivalents			
Cash and cash equivalents	3 820	56 879	10 839
Total current assets	52 091	92 936	57 957
TOTAL ASSETS	81 028	129 038	88 413

BALANCE SHEET FOR THE PARENT COMPANY

Amounts in TSEK	2022 Mar 31	2021 Mar 31	2021 Dec 31
EQUITY AND LIABILITIES			
Equity			
Share capital	11 549	11 397	11 549
Fund for development expenditure	4 384	5 518	4 386
Total restricted equity	15 933	16 914	15 935
Non-restricted equity			
Share premium reserve	234 674	231 349	234 674
Retained earnings	-202 773	-157 681	-156 549
Result for the period	-16 044	-8 933	-46 225
Total non-restricted equity	15 858	64 735	31 900
Total equity	31 791	81 649	47 834
Provisions			
Other provisions	533	528	530
Noncurrent liabilities			
Liabilities to credit institutions	833	3 013	1 333
Other noncurrent liabilities	36 502	27 000	27 000
Total noncurrent liabilities	37 336	30 013	28 333
Current liabilities			
Liabilities to credit institutions	2 180	2 720	2 360
Advanced payment from customers	779	2 590	946
Accounts payable	2 796	5 982	3 685
Other liabilities	1 196	884	1 408
Accrued expenses and deferred income	4 417	4 672	3 317
Total current liabilities	11 369	16 848	11 716
Total liabilities	49 238	47 389	40 579
TOTAL EQUITY AND LIABILITIES	81 028	129 038	88 413

REPORT OF CHANGES IN EQUITY FOR THE PARENT COMPANY

Amounts in TSEK	2022 Jan - Mar	2021 Jan - Mar	2021 Jan - Dec
Total equity at the beginning of the period	47 834	90 601	90 601
Rights issue	0	0	3 453
Premiums for issued / repurchased warrants	0	-19	5
Total comprehensive income for the period	-16 044	-8 933	-46 225
Total equity at the end of the period	31 790	81 649	47 834

CASH FLOW ANALYSIS FOR THE PARENT COMPANY

Amounts in TSEK	2022 Jan - Mar	2021 Jan - Mar	2021 Jan - Dec
Operating activities			
Operating profit/loss	-15 752	-7 842	-42 075
Adjustment for items not affecting cash flow	2 354	2 276	10 412
Interest paid	-1 229	-3 371	-5 286
Income taxes received/paid	0	0	0
Cash flow from operating activities before changes in working capital	-14 627	-8 937	-36 949
<i>Cash flow from changes in working capital</i>			
Increase (-) / decrease (+) of inventories	1 170	-723	2 182
Increase (-) / decrease (+) of operating receivables	-1 874	1 589	-13 289
Increase (+) / decrease (-) of operating liabilities	-61	2 895	-1 795
Cash flow from operating activities	-15 392	-5 176	-49 851
Investing activities			
Acquisitions in intangible assets	-655	-3 328	-5 122
Acquisitions in tangible assets	-287	-29	-808
Acquisitions in group companies	-27	-78	-281
Compensation for divested financial assets	0	0	0
Cash flow from investing activities	-969	-3 435	-6 211
Financing activities			
Rights issue for the year	0	0	3 454
Premiums for issued/reissued warrants	0	-19	-19
New borrowings	10 000	0	0
Amortization of financial loans	-680	-680	-2 720
Cash flow from financing activities	9 320	-699	715
Total cash flow for actual period	-7 041	-9 310	-55 347
Cash and cash equivalents, opening balance	10 839	66 183	66 183
Exchange rate difference in cash and cash equivalents	22	6	3
Cash and cash equivalents, closing balance	3 820	56 879	10 839

NOTES

NOTE 1 GENERAL INFORMATION

This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664-5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is Forskargatan 20 G, 151 36 Södertälje, Sweden. The main operation of the group is sales of silica-based chromatography products, and research and development of pharmaceutical products.

Nanologica AB has five subsidiaries: Nanghavi AB, Nanologica Australia Ltd, Nanologica Black AB, Nanologica Yellow AB and Nlab Bioscience S.A. Nanologica Australia Ltd has limited activities linked to research and Nlab Bioscience S.A is under liquidation. The other companies are dormant at the time of the publication of the report.

The interim report for the first quarter 2022 has been approved for publication on April 29, 2022, in accordance with a board decision on April 28, 2022.

NOTE 2 ACCOUNTING PRINCIPLES

The consolidated financial statements for Nanologica AB (publ) have been prepared in accordance with IFRS (International Financial Reporting Standards) as adopted by the EU, the Annual Accounts Act and the Swedish Financial Reporting Board's RFR 1 Supplementary Accounting Rules for Groups. The parent company's financial statements are presented in accordance with the Swedish Annual Accounts Act and RFR 2 Accounting for Legal Entities.

This interim report is presented in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. Disclosures in accordance with IAS 34 are presented both in notes and elsewhere in interim report. The accounting principles and calculation methods applied are in accordance with those described in the Annual Report 2020. The guidelines of the European Securities and Markets Authority (ESMA) on alternative performance measures have been applied. This involves disclosure requirements for financial measures that are not defined by IFRS. For performance measures not defined by IFRS, see the Definition of key figures section.

NOTE 3 IMPORTANT SOURCES OF UNCERTAINTY IN ESTIMATES

Important estimates and assessments are described in detail in the Annual Report 2021 on pages 80–81. No significant changes in estimates and assessments have been noted for the reporting period. This report contains assumptions, assessments and estimates that affect the content of the financial statements. Actual outcomes may differ from these assessments and estimates.

NOTE 4 SEGMENTS

An operating segment is part of a group that conducts operations from which it can generate revenue and incur costs, and for which independent financial information is available. The group's division into operating segments is consistent with the internal reports that the group's highest executive decision-makers use to monitor operations and allocate resources among operating segments. The CEO is the group's highest executive decision-maker. In Nanologica, it is therefore the reports that the CEO receives on earnings in different parts of the group that form the basis for the segment information. Two operating segments have been identified in the group: Drug Development and Chromatography. Under the headline Business support, support functions that are not directly attributable to commercial segments is reported (e.g., the company's management, communication/marketing, finance, etc.). Segment information is provided only for the group.

In the table below, the business area Chromatography is titled Chroma, and the business area Drug Development is titled DD.

	2022 Jan - Mar			
	Chroma	DD	Corp Function	Total
Net sales	270	0	0	270
Raw materials, consumables and change in inventory	-1 350	-7	0	-1 357
Gross profit	-1 080	-7	0	-1 087
Other operating items	-5 646	-3 026	-5 833	-14 505
Operating profit/loss	-6 726	-3 033	-5 833	-15 592
Net finance			-323	-323
Profit/loss after financial items	-6 726	-3 033	-6 156	-15 915

	2021 Jan - Mar			
	Chroma	DD	Corp Function	Total
Net sales	141	5 481	0	5 622
Raw materials, consumables and change in inventory	131	-2 475	0	-2 344
Gross profit	272	3 006	0	3 278
Other operating items	-3 596	-3 118	-3 333	-10 047
Operating profit/loss	-3 324	-111	-3 332	-6 768
Net finance			-1 077	-1 077
Profit/loss after financial items	-3 324	-111	-4 409	-7 845

NOTE 5 DISTRIBUTION OF INCOME

Nanologica's distribution of revenues for sales of goods and provision of services at a specific time and over time divided per geographic market and reported separately for major customers.

Composition of net sales, per segment and region (TSEK)	2022	2021	2021
	Jan - Mar	Jan - Mar	Jan - Dec
Chromatography	270	141	1 911
<i>China</i>	187	13	1 309
<i>USA</i>	0	0	103
<i>Rest of the World</i>	83	128	499
Drug development	0	5 481	10 361
<i>Sweden</i>	0	4 879	9 243
<i>Rest of the World</i>	0	602	1 118
Business development	0	0	642
<i>Rest of the World</i>	0	0	642
	270	5 622	12 914

Composition of net sales, large customers (TSEK)	2022	2021	2021
	Jan - Mar	Jan - Mar	Jan - Dec
Customer A - Drug Development	0	4 880	9 244
Customer A (%)	0%	87%	72%
Customer B - Drug Development	0	602	1 118
Customer B (%)	0%	11%	9%
Customer C - Chromatography	187	13	1 309
Customer C (%)	69%	0%	10%
Others	83	127	1 243
Others (%)	31%	2%	10%
	270	5 622	12 914

NOTE 6 FINANCIAL ASSETS VALUED AT FAIR VALUE

Fair value valuation

IFRS 13 Fair value valuation contains a valuation hierarchy regarding input to the valuations. This valuation hierarchy is divided into three levels, consisting of:

- Level 1 - Quoted prices on active markets for identical assets and liabilities
- Level 2 - Observable inputs for the asset or liability other than quoted prices including in level 1, either directly or indirectly (i.e. derived from quotations).
- Level 3 - Input of the asset or liability that is not based on observable market data (i.e. non-observable inputs).

Short-term financial investments

Holdings in short-term financial investments are continuously measured at fair value with a change in value in profit or loss. Holdings in listed shares are continuously valued at fair value according to Level 1 of the valuation hierarchy. Listed holdings are valued on the basis of the share price at the balance sheet date.

Valuation of financial assets at fair value (TSEK)	2022 Jan - Mar	2021 Jan - Mar	2021 Jan - Dec
Vicore Pharma Holding AB (publ), Nasdaq Stockholm Small Cap	448	-256	-902

Financial assets valued at fair value via the income statement (TSEK)	2022 Mar 31	2021 Mar 31	2021 Dec 31
Vicore Pharma Holding AB (publ), Nasdaq Stockholm Small Cap			
- number of shares	51 285	51 285	51 285
- market value, Nasdaq Stockholm Small Cap (SEK)	22,65	26,50	13,92
Book value	1 162	1 359	714

NOTE 7 INVENTORIES

Amounts in TSEK	2022 Mar 31	2021 Mar 31	2021 Dec 31
Raw materials	53	85	53
Semi-finished products and production in progress	1026	4762	2188
Finished products	159	465	167
Sum	1 238	5 312	2 408

NOTE 8 SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

The launch of the company's silica for preparative chromatography starts.

A loan of MSEK 20 is taken out in April within the credit facility of up to MSEK 50 that was signed with Flerie Invest AB in January.

NOTE 9 DEFINITION OF KEY FIGURES

In this report, the company recognizes certain financial ratios that are not defined by IFRS. Alternative key ratios should not be seen as substitutes for financial information presented in accordance with IFRS, but as a complement.

Key figure	Definition	Motivation for use
Average number of shares during the period	Calculated as an average of the number of ordinary shares outstanding during the reporting period on a daily basis after redemption and repurchase.	In order to obtain an average value over time in the event of a change in the number of shares during the period
Equity per share, SEK	Total equity divided by the number of outstanding shares at the end of the period.	Key figures used to highlight the owners' share of the company's net assets per share.
Equity ratio, %	Equity divided by the balance sheet total.	Key figures showing the proportion of assets financed with equity. The aim is to be able to assess the group's ability to pay in the long term.
Equity	The group's reported equity at the balance sheet date.	Financial key ratio to assess the financial situation.
Number of shares	The number of ordinary shares outstanding is calculated at the balance sheet date.	Key figures to show shareholders the total number of shares and put in relation to other figures in the income statement and balance sheet.
Operating profit/loss	Operating profit/loss before financial items and tax.	Financial key ratios that the company regards as relevant to understand the generation of earnings in the business.
Operating profit/loss before tax	Profit/loss before tax.	Financial key ratio that the company considers relevant to understand the results of the entire business.

Derivation

Derivation	2022 Mar 31	2021 Mar 31	2021 Dec 31
A. Equity according to the balance sheet (TSEK)	35 681	85 103	51 596
B. Total assets according to balance sheet (TSEK)	90 388	138 545	98 316
"A/B" = Equity ratio (%)	39%	61%	52%
A. Equity according to the balance sheet (TSEK)	35 681	85 103	51 596
B. Number of shares before and after dilution*	28 165 826	27 794 480	28 165 826
"A/B"1000 = Equity per share (SEK)*	1,27	3,06	1,83

GROUP QUARTERLY DATA

Amounts in TSEK unless otherwise stated	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2
Statement of comprehensive income								
Net sales	270	676	2 119	4 497	5 622	6 071	2 089	4 321
Total operating expenses	-15 122	-13 406	-13 763	-13 280	-13 750	-9 958	-8 659	-11 648
Operating profit/loss (EBIT) *	-15 592	-14 108	-11 718	-8 094	-6 768	-3 648	-5 795	-4 097
Operating margin,%	neg	neg	neg	neg	neg	neg	neg	neg
Total financial investments	-323	-1 114	-827	-1 122	-1 077	-1 779	-104	-71
Profit/loss before income tax	-15 915	-15 222	-12 546	-9 216	-7 845	-5 427	-5 899	-4 168
Consolidated financial position								
Total noncurrent assets	39 403	41 512	43 270	46 651	46 864	45 180	43 826	42 453
Total current assets	50 985	56 803	72 282	84 620	91 681	101 165	105 720	118 786
Cash and cash equivalents	3 969	10 987	28 624	44 795	57 069	66 364	82 203	89 970
Total equity	35 681	51 596	66 794	79 340	85 103	92 966	98 604	103 802
Total noncurrent liabilities	40 515	32 222	33 416	34 600	34 422	35 645	36 875	38 080
Total current liabilities	14 193	14 498	15 341	17 331	19 021	17 735	14 067	19 357
Consolidated statement of cash flow								
Cash flow from operating activities	-14 744	-15 213	-14 152	-13 652	-3 476	-12 854	-4 422	-18 046
Cash flow from investing activities	-942	-1 095	-690	-866	-4 598	-1 573	-2 875	-1 597
Cash flow from financing activities	8 646	-1 329	-1 329	2 249	-1 230	-1 397	-479	108 354
Total cash flow for actual period	-7 040	-17 637	-16 171	-12 269	-9 304	-15 824	-7 776	88 710
Other Key Figures								
Equity ratio, % *	39,5%	52,5%	57,8%	60,4%	61,4%	63,5%	65,9%	64,4%
Number of employees at the end of the period	18	17	20	20	20	19	20	19
Number of employees on average during the period	17	17	20	20	18	19	20	19
Average number of employees and consultants during the period	20	20	23	23	21	20	20	19
Data per share								
Earnings per share before and after dilution, SEK	-0,57	-0,54	-0,45	-0,33	-0,28	-0,20	-0,21	-0,18
Equity per share (before dilution), SEK *	1,27	1,83	2,37	2,82	3,06	3,35	3,56	3,75
Cash flow from operating activities per share, SEK	-0,52	-0,54	-0,50	-0,49	-0,13	-0,46	-0,16	-0,77
Share price at the end of the period, SEK	16,75	13,70	14,45	15,15	16,45	13,40	14,00	11,05
Number of shares before dilution on average during the period	28 165 826	28 165 826	28 165 826	27 918 262	27 788 212	27 723 273	27 699 077	23 513 439
Number of shares before dilution at the end of the period	28 165 826	28 165 826	28 165 826	28 165 826	27 794 480	27 776 850	27 699 077	27 699 077
Number of warrants at the end of the period	1 719 949	1 719 949	919 949	919 949	1 291 745	1 336 875	1 414 648	467 199

* Alternative key figures that are not defined by IFRS. For definition, please see note 9.



Nanologica AB (publ)

Forskargatan 20 G

151 36 Södertälje

Tel: 08-410 749 49

www.nanologica.com